Enhancement of Corticosteroid Efficacy in COPD
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 45 - Any |
| Updated: | 6/21/2018 |
| Start Date: | December 2014 |
| End Date: | August 2016 |
This is a pilot study designed to evaluate the effects of theophylline and roflumilast on
circulating Histone deacetylase (HDAC) levels in subjects with COPD, and the bronchodilator
effects of corticosteroids. Studies will be performed in 10 subjects with COPD nonresponsive
to bronchodilators. Subjects will receive theophylline tablets for 1 week, followed by
measurement of circulating HDAC and the acute effect of oral prednisone on the bronchodilator
response to inhaled beta agonist. Roflumilast tablets will be added to the theophylline for a
further week and the studies repeated. The study will provide preliminary data on the effects
of theophylline and roflumilast on circulating HDAC levels and the effects of corticosteroids
on the beta agonist bronchodilator response in COPD.
circulating Histone deacetylase (HDAC) levels in subjects with COPD, and the bronchodilator
effects of corticosteroids. Studies will be performed in 10 subjects with COPD nonresponsive
to bronchodilators. Subjects will receive theophylline tablets for 1 week, followed by
measurement of circulating HDAC and the acute effect of oral prednisone on the bronchodilator
response to inhaled beta agonist. Roflumilast tablets will be added to the theophylline for a
further week and the studies repeated. The study will provide preliminary data on the effects
of theophylline and roflumilast on circulating HDAC levels and the effects of corticosteroids
on the beta agonist bronchodilator response in COPD.
1. SUBJECTS: 10 Stable patients >45 years of age, with an established diagnosis of COPD
(18), with FEV1 <60% predicted, FEV1/FVC <70% and <+15% FEV1 response to bronchodilator
will be recruited. Patients of both genders will be included.
2. TESTS
a) Blood: i) HDAC 2 in peripheral blood mononuclear cells: ii) Serum theophylline level
b) Spirometry for measurement of FVC, FEV1 and FEV1/FVC
PROCEDURES Visit 1.
1. After providing informed consent, subjects will receive a brief history and
physical examination
2. Blood will be drawn from a peripheral vein for HDAC2 levels (2 ml).
3. Each subject will undergo baseline spirometry, which will be repeated after 3
inhalations of an albuterol inhaler.
c) Subjects will be asked to continue their regular treatment regimen, including long
and short acting beta agonists and anticholinergics, as well as inhaled steroids.
d) Theophylline tablets extended-release 12 hr formulation, 300 mg orally taken every 12
hr will be dispensed, and the subject will return one week later for Visit 2. The
subject will be asked to refrain from using his/her long acting beta agonists and
anticholinergics for one day (24 hours) prior to Visit 2, and not to use the short
acting beta agonist or take any caffeine containing drinks on the morning of visit 2.
The subject will be asked to inform the P. I. should there be any adverse event.
Subjects discontinuing the study drugs because of side effects will be withdrawn from
the study.
Visit 2.
1. A brief history and physical examination will be performed and the subject will be
asked about any change in symptoms.
2. Blood (5 ml) will be drawn from a peripheral vein for HDAC2 and theophylline levels
3. After baseline spirometry the subject will be given a single dose of 40 mg
prednisone tablets.
4. After 120 minutes, spirometry will be repeated, followed by 3 puffs of albuterol
inhaler and repeat spirometry.
The subject will then be asked to continue the theophylline tablets and in addition will
be given roflumilast tablets 500 mcg orally once daily, and asked to return one week
later for Visit 3.
The subject will be asked to refrain from using his/her long acting beta agonists and
anticholinergics for one day (24 hours) prior to Visit 3, and not to use the short
acting beta agonist or take any caffeine containing drinks on the morning of visit 3.
The subject will be asked to inform the P. I. should there be any adverse event.
Visit 3
1. A brief history and physical examination will be performed and the subject will be
asked about any change in symptoms.
2. Blood (5 ml) will be drawn from a peripheral vein for HDAC2 measurement.
3. After baseline spirometry the subject will be given a single dose of prednisone
tablets in a dose of 40 mg.
4. After 120 minutes, spirometry will be repeated, followed by 3 puffs of albuterol
inhaler and repeat spirometry.
The subject will then have completed the study and will return to his/her previous
treatment regimen.
Data analysis:
Results will be compared in terms of baseline vs drug by paired t test for change in
FEV1 and FEV1/FVC as well as peripheral blood mononuclear blood HDAC2 levels. The
relationship between FEV1 and FEV1/FVC and blood HDAC2 levels will be examined by
correlation analysis.
Expected results It is expected that with both theophylline and roflumilast treatment
there will be a significant (p<0.05) increase in HDAC2 levels. It is also expected that
with both theophylline and roflumilast treatment there will be a significant (p<0.05)
increase in the bronchodilator response after the steroid dose, thereby supporting the
hypothesis.
It is also possible that there will be no effect on spirometry of either treatment; this
would indicate that an increase in HDAC2 does not improve steroid responsiveness.
(18), with FEV1 <60% predicted, FEV1/FVC <70% and <+15% FEV1 response to bronchodilator
will be recruited. Patients of both genders will be included.
2. TESTS
a) Blood: i) HDAC 2 in peripheral blood mononuclear cells: ii) Serum theophylline level
b) Spirometry for measurement of FVC, FEV1 and FEV1/FVC
PROCEDURES Visit 1.
1. After providing informed consent, subjects will receive a brief history and
physical examination
2. Blood will be drawn from a peripheral vein for HDAC2 levels (2 ml).
3. Each subject will undergo baseline spirometry, which will be repeated after 3
inhalations of an albuterol inhaler.
c) Subjects will be asked to continue their regular treatment regimen, including long
and short acting beta agonists and anticholinergics, as well as inhaled steroids.
d) Theophylline tablets extended-release 12 hr formulation, 300 mg orally taken every 12
hr will be dispensed, and the subject will return one week later for Visit 2. The
subject will be asked to refrain from using his/her long acting beta agonists and
anticholinergics for one day (24 hours) prior to Visit 2, and not to use the short
acting beta agonist or take any caffeine containing drinks on the morning of visit 2.
The subject will be asked to inform the P. I. should there be any adverse event.
Subjects discontinuing the study drugs because of side effects will be withdrawn from
the study.
Visit 2.
1. A brief history and physical examination will be performed and the subject will be
asked about any change in symptoms.
2. Blood (5 ml) will be drawn from a peripheral vein for HDAC2 and theophylline levels
3. After baseline spirometry the subject will be given a single dose of 40 mg
prednisone tablets.
4. After 120 minutes, spirometry will be repeated, followed by 3 puffs of albuterol
inhaler and repeat spirometry.
The subject will then be asked to continue the theophylline tablets and in addition will
be given roflumilast tablets 500 mcg orally once daily, and asked to return one week
later for Visit 3.
The subject will be asked to refrain from using his/her long acting beta agonists and
anticholinergics for one day (24 hours) prior to Visit 3, and not to use the short
acting beta agonist or take any caffeine containing drinks on the morning of visit 3.
The subject will be asked to inform the P. I. should there be any adverse event.
Visit 3
1. A brief history and physical examination will be performed and the subject will be
asked about any change in symptoms.
2. Blood (5 ml) will be drawn from a peripheral vein for HDAC2 measurement.
3. After baseline spirometry the subject will be given a single dose of prednisone
tablets in a dose of 40 mg.
4. After 120 minutes, spirometry will be repeated, followed by 3 puffs of albuterol
inhaler and repeat spirometry.
The subject will then have completed the study and will return to his/her previous
treatment regimen.
Data analysis:
Results will be compared in terms of baseline vs drug by paired t test for change in
FEV1 and FEV1/FVC as well as peripheral blood mononuclear blood HDAC2 levels. The
relationship between FEV1 and FEV1/FVC and blood HDAC2 levels will be examined by
correlation analysis.
Expected results It is expected that with both theophylline and roflumilast treatment
there will be a significant (p<0.05) increase in HDAC2 levels. It is also expected that
with both theophylline and roflumilast treatment there will be a significant (p<0.05)
increase in the bronchodilator response after the steroid dose, thereby supporting the
hypothesis.
It is also possible that there will be no effect on spirometry of either treatment; this
would indicate that an increase in HDAC2 does not improve steroid responsiveness.
Inclusion Criteria:
- Established diagnosis of COPD with FEV1 <60% predicted
- FEV1/FVC <70% and <+15% FEV1 response to bronchodilator.
- Patients of both genders will be included.
- IRB approved written informed consent will be obtained from each subject.
Exclusion Criteria:
1. Recent (<1 month) exacerbation of COPD,
2. Known hypersensitivity to beta agonists, theophylline, steroids, or roflumilast.
3. Current or recent (<2 weeks) treatment with oral steroids, theophylline or other
methylxanthines, or roflumlast.
4. Diagnosis or history of asthma, uncontrolled hypertension, or congestive heart
failure.
5. History of Cardiac arrhythmia
6. History of seizures.
7. History of Liver disease
8. Gastrointestinal disease, including history of peptic ulcer disease.
9. Current infection or antibiotic treatment.
10. History of depression or psychiatric disease.
We found this trial at
1
site
Click here to add this to my saved trials
